Antibody Responses and the Effects of Clinical Drugs in COVID-19 Patients.
Antibody Responses and the Effects of Clinical Drugs in COVID-19 Patients.
复制标题
DOI：
10.3389/fimmu.2021.580989
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Xia J
中科院分区：
文献类型：
--
作者：
Wei L;Shang Y;Liu X;Li X;Chen G;Liang S;Zou Z;Ding T;Hong Z;Wu M;Xia J
2019冠状病毒病（COVID-19）于2019年12月左右出现，目前已成为全球流行病。在COVID-19患者的血清或血浆中可以检测到针对SAS-COV-2的特异性抗体，但这些抗体的临床价值以及临床药物对体液反应的影响尚未得到充分证实。本研究在中山大学第五附属医院采集了36例新冠肺炎确诊患者的血浆样本112份。ELISA法检测sars - cov -2受体结合域（RBD）和刺突蛋白亚基1 （S1）的IgG和IgM抗体。我们发现，COVID-19患者在感染后产生了针对SARS-CoV-2的特异性抗体，并且在发病后2 ~ 3周内抗rbd IgG水平与SARS-CoV-2核酸阳性到阴性转化的时间呈负相关。症状严重的患者在发病后2 ~ 3周内抗rbd IgG水平升高。使用氯喹对患者的抗体滴度无显著影响，但降低了c反应蛋白（CRP）水平。使用抗病毒药物（洛匹那韦/利托那韦或阿比多）可降低抗体滴度和外周血淋巴细胞计数。而糖皮质激素治疗的外周血淋巴细胞计数降低，CRP、乳酸脱氢酶（LDH）、α-羟基丁酸脱氢酶（α-HBDH）、总胆红素（TBIL）、直接胆红素（DBIL）水平升高。这些结果提示抗rbd IgG可能在发病后2 ~ 3周内对宿主的体液反应提供早期保护，不同药物的临床治疗在体液和炎症反应中表现出不同的作用。
The coronavirus disease 2019 (COVID-19) emerged around December 2019 and have become a global epidemic disease currently. Specific antibodies against SAS-COV-2 could be detected in COVID-19 patients’ serum or plasma, but the clinical values of these antibodies as well as the effects of clinical drugs on humoral responses have not been fully demonstrated. In this study, 112 plasma samples were collected from 36 patients diagnosed with laboratory-confirmed COVID-19 in the Fifth Affiliated Hospital of Sun Yat-sen University. The IgG and IgM antibodies against receptor binding domain (RBD) and spike protein subunit 1 (S1) of SAS-COV-2 were detected by ELISA. We found that COVID-19 patients generated specific antibodies against SARS-CoV-2 after infection, and the levels of anti-RBD IgG within 2 to 3 weeks from onset were negatively associated with the time of positive-to-negative conversion of SARS-CoV-2 nucleic acid. Patients with severe symptoms had higher levels of anti-RBD IgG in 2 to 3 weeks from onset. The use of chloroquine did not significantly influence the patients’ antibody titer but reduced C-reaction protein (CRP) level. Using anti-viral drugs (lopinavir/ritonavir or arbidol) reduced antibody titer and peripheral lymphocyte count. While glucocorticoid therapy developed lower levels of peripheral lymphocyte count and higher levels of CRP, lactate dehydrogenase (LDH), α-Hydroxybutyrate dehydrogenase(α-HBDH), total bilirubin (TBIL), direct bilirubin (DBIL). From these results, we suggested that the anti-RBD IgG may provide an early protection of host humoral responses against SAS-COV-2 infection within 2 to 3 weeks from onset, and clinical treatment with different drugs displayed distinct roles in humoral and inflammatory responses.
登录
查看更多内容
影响因子：
5
作者：
Padoan, Andrea;Sciacovelli, Laura;Plebani, Mario
通讯作者：
Plebani, Mario
影响因子：
82.9
作者：
Long, Quan-Xin;Liu, Bai-Zhong;Huang, Ai-Long
通讯作者：
Huang, Ai-Long
影响因子：
12.7
作者：
Li, Zhengtu;Yi, Yongxiang;Ye, Feng
通讯作者：
Ye, Feng
用糖固醇治疗严重的急性呼吸道综合征：广州体验。
影响因子：
9.6
作者：
Chen RC;Tang XP;Tan SY;Liang BL;Wan ZY;Fang JQ;Zhong N
通讯作者：
Zhong N
影响因子：
20.6
作者：
Huang, Mingxing;Li, Man;Shan, Hong
通讯作者：
Shan, Hong